ATE276740T1 - Pharmazeutische zusammensetzung zur diagnose von lungenkrankheiten - Google Patents

Pharmazeutische zusammensetzung zur diagnose von lungenkrankheiten

Info

Publication number
ATE276740T1
ATE276740T1 AT96926158T AT96926158T ATE276740T1 AT E276740 T1 ATE276740 T1 AT E276740T1 AT 96926158 T AT96926158 T AT 96926158T AT 96926158 T AT96926158 T AT 96926158T AT E276740 T1 ATE276740 T1 AT E276740T1
Authority
AT
Austria
Prior art keywords
lung
acceptable salt
sample
mucus
composition
Prior art date
Application number
AT96926158T
Other languages
German (de)
English (en)
Inventor
Richard C Boucher Jr
Original Assignee
Univ North Carolina
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina filed Critical Univ North Carolina
Application granted granted Critical
Publication of ATE276740T1 publication Critical patent/ATE276740T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
AT96926158T 1995-07-31 1996-07-24 Pharmazeutische zusammensetzung zur diagnose von lungenkrankheiten ATE276740T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/509,052 US5628984A (en) 1995-07-31 1995-07-31 Method of detecting lung disease
PCT/US1996/012377 WO1997005195A1 (en) 1995-07-31 1996-07-24 Method of detecting lung disease

Publications (1)

Publication Number Publication Date
ATE276740T1 true ATE276740T1 (de) 2004-10-15

Family

ID=24025091

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96926158T ATE276740T1 (de) 1995-07-31 1996-07-24 Pharmazeutische zusammensetzung zur diagnose von lungenkrankheiten

Country Status (17)

Country Link
US (4) US5628984A (enExample)
EP (1) EP0841900B1 (enExample)
JP (2) JP3623237B2 (enExample)
KR (1) KR100283306B1 (enExample)
CN (1) CN1121441C (enExample)
AT (1) ATE276740T1 (enExample)
AU (1) AU705528B2 (enExample)
BR (1) BR9610059A (enExample)
CA (1) CA2226892A1 (enExample)
DE (1) DE69633449T2 (enExample)
ES (1) ES2229281T3 (enExample)
IL (1) IL122803A0 (enExample)
MX (1) MX9800933A (enExample)
NO (1) NO980279L (enExample)
NZ (1) NZ313864A (enExample)
WO (1) WO1997005195A1 (enExample)
ZA (1) ZA966425B (enExample)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096721A (en) * 1995-04-13 2000-08-01 Milkhaus Laboratory, Inc. Method for treating mucositis by sublingual administration of DNA
US5948768A (en) * 1995-04-13 1999-09-07 Milkhaus Laboratory Treatment of otitis media by sublingual administration of DNA
AU716486B2 (en) * 1995-04-13 2000-02-24 Milkhaus Laboratory, Inc. Methods for treating respiratory disease
US5635160A (en) 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US5968913A (en) * 1996-07-03 1999-10-19 Inspire Pharmaceuticals, Inc. Pharmaceutical compositions of uridine triphosphate
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US6159952A (en) * 1996-11-07 2000-12-12 Inspire Pharmaceuticals, Inc. Method of treating bronchitis with uridine triphosphate and related compounds
US6998121B2 (en) 2003-01-23 2006-02-14 Milkhaus Laboratory, Inc. Method of treatment of connective tissue disorders by administration of streptolysin O
JP3723227B2 (ja) 1997-07-25 2005-12-07 インスパイアー ファーマシューティカルズ，インコーポレイティド ジ（ウリジン５’）−テトラホスフェート及びその塩の大規模生産のための方法
US6872710B2 (en) * 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
TW593331B (en) 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
DE69828892D1 (de) * 1997-08-29 2005-03-10 Univ North Carolina Verwendung von uridin-5'-diphosphat und analoge zur behandlung von lungenerkrankungen
EP1139746A4 (en) * 1998-12-22 2003-09-17 Univ North Carolina CONNECTIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISEASES AND THE ADMINISTRATION OF MEDICINAL SUBSTANCES
US6926911B1 (en) * 1998-12-22 2005-08-09 The University Of North Carolina At Chapel Hill Compounds and methods for the treatment of airway diseases and for the delivery of airway drugs
MXPA01008547A (es) 1999-02-26 2003-06-06 Inspire Pharmaceuticals Inc Metodo para promover la hidratacion de mucosas con ciertos difosfatos de uridina, adenina y citidina, y analogos de estos.
EP1190249A2 (en) * 1999-06-08 2002-03-27 University Of Iowa Research Foundation Compounds and methods to enhance raav transduction
US7241447B1 (en) * 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7115585B2 (en) * 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
AR034635A1 (es) 2001-06-25 2004-03-03 Inspire Pharmaceuticals Inc Lubricacion de las articulaciones con agonistas del receptor purinergico p2y
JP3823162B2 (ja) * 2001-07-31 2006-09-20 株式会社エイアンドティー 臨床検査分析装置、臨床検査分析方法および臨床検査分析プログラム
AR037263A1 (es) * 2001-11-06 2004-11-03 Inspire Pharmaceuticals Inc Uso de una formulacion farmaceutica para la manufactura de un medicamento para el tratamiento o prevencion de enfermedades inflamatorias
US20060196365A1 (en) * 2001-12-11 2006-09-07 Garman Michael H Combined water cooler and hot beverage maker
US6858615B2 (en) 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
EP1531795A4 (en) 2002-05-02 2011-02-23 Harvard College FORMULATIONS FOR LIMITING THE RETENTION OF LUNG INFECTIONS
US20050220720A1 (en) * 2002-05-02 2005-10-06 David Edwards Formulations limiting spread of pulmonary infections
US7629312B2 (en) 2003-01-23 2009-12-08 Milkhaus Laboratory, Inc. Method of treatment of tendonitis by administration of streptolysin O
WO2004089423A2 (en) * 2003-03-31 2004-10-21 University Of Iowa Research Foundation Pharmico-gene theraphy of epithelial sodium channel associated disoders
KR101153254B1 (ko) 2003-06-26 2012-07-02 바이오트론 리미티드 항바이러스 화합물 및 방법
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US20090253714A1 (en) * 2003-08-20 2009-10-08 Johnson Michael R Methods of reducing risk of infection from pathogens
AU2004292992A1 (en) * 2003-11-24 2005-06-09 Georgia State University Research Foundation, Inc Fused ring dicationic anti-protozoan agents and their prodrugs
US20050207983A1 (en) * 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
WO2005086754A2 (en) * 2004-03-08 2005-09-22 Georgia State University Research Foundation, Inc. Dicationic compounds for activity against trichomonas vaginalis
US20070099968A1 (en) * 2004-06-26 2007-05-03 Biotron Limited Antiviral compounds and methods
GB0417886D0 (en) * 2004-08-11 2004-09-15 Univ Cardiff Method and means for enhanced pulmonary delivery
WO2006096757A2 (en) * 2005-03-07 2006-09-14 The University Of North Carolina At Chapel Hill Inhibitors of reca activities for control of antibiotic-resistant bacterial pathogens
AU2006201739A1 (en) * 2005-05-05 2006-11-23 The University Of North Carolina At Chapel Hill Synthesis and antiprotozoal activity of dicationic 3,5-diphenylisoxazoles
KR20080018872A (ko) * 2005-05-18 2008-02-28 풀매트릭스 인코퍼레이티드 점막 내층의 생물물리학적 특성의 변화를 위한 제제
AU2006202083A1 (en) 2005-06-03 2006-12-21 Reto Brun Linear dicationic terphenyls and their aza analogues as antiparasitic agents
US7964619B2 (en) 2005-06-03 2011-06-21 The University Of North Carolina At Chapel Hill Teraryl components as antiparasitic agents
US20100249175A1 (en) * 2005-12-02 2010-09-30 Wilson W David Dicationic compounds which selectively recognize G-quadruplex DNA
AU2007243184A1 (en) * 2006-04-28 2007-11-08 University Of Iowa Research Foundation Methods and compounds to modulate parvovirus transduction of mammalian cells or to alter virus infection, method to identify a viral receptor or co-receptor
US20080260863A1 (en) * 2007-04-20 2008-10-23 Pre Holding, Inc. Compositions for mucociliary clearance and methods for administering same
US8088385B2 (en) 2007-06-18 2012-01-03 University Of Louisville Research Foundation Inc. PFKB3 inhibitor for the treatment of a proliferative cancer
US20100280098A1 (en) * 2007-10-05 2010-11-04 Juliano Rudolph L Receptor targeted oligonucleotides
CA2702094C (en) 2007-10-10 2018-05-01 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
WO2009051796A2 (en) * 2007-10-17 2009-04-23 The University Of North Carolina At Chapel Hill 2,5-diaryl selenophene compounds, aza 2,5-diaryl thiophene compounds, and their prodrugs as antiprotozoal agents
KR20100135886A (ko) 2008-04-09 2010-12-27 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 액틴 세포 골격의 재배열 및 세포간 갭 형성을 조절하는 방법
US20110224227A1 (en) * 2008-10-01 2011-09-15 Sharpless Norman E Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
JP2012504645A (ja) 2008-10-01 2012-02-23 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 健康な細胞に対する電離放射線の影響を低下させる又は防止するための医薬組成物
PT2410981T (pt) 2009-03-26 2017-05-25 Pulmatrix Inc Formulações em pó seco e métodos para tratar doenças pulmonares
CN102458443A (zh) 2009-05-13 2012-05-16 北卡罗来纳大学查珀尔希尔分校 细胞周期蛋白依赖性激酶抑制剂及使用方法
WO2011008756A1 (en) 2009-07-13 2011-01-20 Irix Pharmaceuticals Synthesis of prostanoids
WO2011011783A1 (en) 2009-07-24 2011-01-27 University Of Tennessee Research Foundation Spectinamides as anti-tuberculosis agents
CN102596010A (zh) * 2009-08-10 2012-07-18 P2科学有限公司 用于诊断狭窄和其他血流受限之病症的utp
JP5922111B2 (ja) * 2010-06-23 2016-05-24 ピーツー−サイエンス・エペイエス 充血剤注入と同時に血圧測定を行う診断目的の動脈用複合カテーテル
CA2809666C (en) 2010-08-30 2020-09-22 Michael M. Lipp Dry powder formulations and methods for treating pulmonary diseases
US8758824B2 (en) 2010-08-30 2014-06-24 Pulmatrix, Inc. Respirably dry powder comprising calcium lactate, sodium chloride and leucine
US9642798B2 (en) 2010-09-29 2017-05-09 Pulmatrix, Inc. Monovalent metal cation dry powders for inhalation
PT3470057T (pt) 2010-09-29 2021-12-03 Pulmatrix Operating Co Inc Pós secos catiónicos compreendendo sais de magnésio
EP2640394A4 (en) 2010-11-17 2015-02-25 Univ North Carolina PROTECTION OF KIDNEY TISSUE FROM ISCHEMIA BY THE INHIBITION OF PROLEVERATIVE KINASES CDK4 AND CDK6
US8945605B2 (en) * 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
CA2838529C (en) * 2011-06-07 2020-03-24 Parion Sciences, Inc. Methods of treatment
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
US20150136130A1 (en) 2012-02-29 2015-05-21 Pulmatrix, Inc. Inhalable dry powders
US9833207B2 (en) 2012-08-08 2017-12-05 William Harrison Zurn Analysis and clearing module, system and method
EP3150585A1 (en) 2012-12-17 2017-04-05 Parion Sciences, Inc. Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
KR20150095870A (ko) 2012-12-17 2015-08-21 패리온 사이언스 인코퍼레이티드 3,5-디아미노-6-클로로-n-(n-(4-페닐부틸)카르밤이미도일)피라진-2-카르복스아미드 화합물
US9962533B2 (en) 2013-02-14 2018-05-08 William Harrison Zurn Module for treatment of medical conditions; system for making module and methods of making module
EP2967050A4 (en) 2013-03-15 2016-09-28 G1 Therapeutics Inc HIGH-ACTIVE ANTINEOPLASTIC AND ANTIPROLIFERATIVE AGENTS
HRP20192168T1 (hr) 2013-03-15 2020-02-21 G1 Therapeutics, Inc. Privremena zaštita normalnih stanica tijekom kemoterapije
RU2015146871A (ru) 2013-04-01 2017-05-10 Пулматрикс, Инк. Сухие порошки с тиотропием
WO2015048736A1 (en) 2013-09-30 2015-04-02 Irix Pharmaceuticals, Inc. Novel synthesis routes for prostaglandins and prostaglandin intermediates using metathesis
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
US9717735B2 (en) 2014-04-17 2017-08-01 G1 Therapeutics, Inc. Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
CN104306028B (zh) * 2014-09-26 2016-08-17 张清玲 一种用于呼吸道细菌16S rRNA基因序列检测的痰液收集方法
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
US11702672B2 (en) 2016-02-08 2023-07-18 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
EP3426787A1 (en) 2016-03-07 2019-01-16 University of Iowa Research Foundation Aav-mediated expression using a synthetic promoter and enhancer
WO2017205739A1 (en) 2016-05-26 2017-11-30 University Of Iowa Research Foundation cis AND trans REQUIREMENTS FOR TERMINAL RESOLUTION OF HUMAN BOCAVIRUS 1
CN109789143A (zh) 2016-07-01 2019-05-21 G1治疗公司 基于嘧啶的抗增殖剂
US10413583B2 (en) 2016-11-30 2019-09-17 The University Of Chicago Synthetic substrates for enzymes that catalyze reactions of modified cysteines and related methods
WO2018132747A1 (en) 2017-01-13 2018-07-19 University Of Iowa Research Foundation Bocaparvovirus small noncoding rna and uses thereof
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
EP3985002B1 (en) 2017-03-01 2025-05-07 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
US20190038623A1 (en) 2017-08-02 2019-02-07 Achillion Pharmaceuticals, Inc. Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
GB2604314A (en) * 2017-09-22 2022-09-07 Nerudia Ltd Device, system and method
US11439608B2 (en) 2017-09-25 2022-09-13 Qun Lu Roles of modulators of intersectin-CDC42 signaling in Alzheimer's disease
WO2019113210A1 (en) 2017-12-05 2019-06-13 Anthos Partners, Lp Phosphonium-based ionic drug conjugates
BR112021004263A2 (pt) 2018-09-06 2021-05-25 Achillion Pharmaceuticals, Inc. formas mórficas de danicopano
US11814391B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
US11807627B2 (en) 2018-09-25 2023-11-07 Achillon Pharmaceuticals, Inc. Morphic forms of complement factor D inhibitors
MX2021007329A (es) 2018-12-17 2021-09-21 Achillion Pharmaceuticals Inc Dosificacion dirigida para el tratamiento de trastornos mediados por el complemento.
EP3941462A4 (en) 2019-03-22 2023-04-05 Achillion Pharmaceuticals, Inc. PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT-MEDIED DISEASES
WO2021236650A1 (en) 2020-05-19 2021-11-25 G1 Therapeutics, Inc. Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1055465A (en) * 1962-09-27 1967-01-18 Vantorex Ltd Allergenic aerosol compositions
NL299931A (enExample) * 1962-10-30
US4132600A (en) * 1977-06-01 1979-01-02 Massachusetts Institute Of Technology Enzymatic noninvasive method for detecting cancer
US4501729A (en) * 1982-12-13 1985-02-26 Research Corporation Aerosolized amiloride treatment of retained pulmonary secretions
FR2571257A1 (fr) * 1984-08-06 1986-04-11 Gros Pierre Composition destinee a l'humidification de la muqueuse rhino-pharyngee
US5470838A (en) * 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
US4950477A (en) * 1988-08-23 1990-08-21 Memorial Hospital For Cancer And Allied Dieseas Method of preventing and treating pulmonary infection by fungi using aerosolized polyenes
GB9027968D0 (en) * 1990-12-22 1991-02-13 Fisons Plc Method of treatment
EP0517573A1 (fr) * 1991-06-05 1992-12-09 Synthelabo Compositions pharmaceutiques pour le traitement des affections des voies respiratoires
US5292498A (en) * 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
US5567689A (en) * 1993-08-13 1996-10-22 The Uab Research Foundation Methods for increasing uridine levels with L-nucleosides
US5656256A (en) * 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease

Also Published As

Publication number Publication date
AU705528B2 (en) 1999-05-27
JP2003073280A (ja) 2003-03-12
US5902567A (en) 1999-05-11
US6214536B1 (en) 2001-04-10
ZA966425B (en) 1997-02-19
ES2229281T3 (es) 2005-04-16
IL122803A0 (en) 1998-09-16
CN1191553A (zh) 1998-08-26
KR100283306B1 (ko) 2001-03-02
CA2226892A1 (en) 1997-02-13
EP0841900A4 (enExample) 1998-06-10
NO980279D0 (no) 1998-01-21
NZ313864A (en) 2000-04-28
NO980279L (no) 1998-01-21
US6133247A (en) 2000-10-17
BR9610059A (pt) 1999-03-02
WO1997005195A1 (en) 1997-02-13
US5628984A (en) 1997-05-13
KR19990036011A (ko) 1999-05-25
DE69633449D1 (de) 2004-10-28
EP0841900B1 (en) 2004-09-22
EP0841900A1 (en) 1998-05-20
JPH11509759A (ja) 1999-08-31
AU6639996A (en) 1997-02-26
CN1121441C (zh) 2003-09-17
JP3623237B2 (ja) 2005-02-23
MX9800933A (es) 1998-05-31
DE69633449T2 (de) 2006-04-27

Similar Documents

Publication Publication Date Title
ATE276740T1 (de) Pharmazeutische zusammensetzung zur diagnose von lungenkrankheiten
US5763447C1 (en) Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
Hughes et al. Chloroquine myopathy
JP2000514461A (ja) ウリジン・トリホスフェート及び関連化合物による副鼻腔炎の治療方法
CA2250188A1 (en) Method of treating ciliary dyskinesia with uridine triphosphates and related compounds
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
ATE225663T1 (de) Verfahren zur behandlung von mittelohrentzündung mittels uridintriphosphaten und verwandten mitteln
EP1014996A4 (en) PREPARATION OF SACCHARIDES AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND OTHER AMYLOIDOSES
ID23375A (id) Metode pengobatan penyakit mata kering dengan agonist-agonist reseptor purinergik
JPH09501413A (ja) 滞留肺分泌物の治療方法
DE69822482D1 (de) Salze von di(uridine 5'-tetraphosphate), verfahren zur herstellung und verwendungen davon
DK0630230T3 (da) Farmaceutiske inhaleringspræparater
Rubin et al. Iodinated glycerol has no effect on pulmonary function, symptom score, or sputum properties in patients with stable chronic bronchitis
CA2240717A1 (en) Method of treating and diagnosing sleep disordered breathing and means for carrying out the method
Stanley et al. Effect of betamethasone and betamethasone with neomycin nasal drops on human nasal mucociliary clearance and ciliary beat frequency.
BR9809678A (pt) Derivados de triptolìdeo úteis no tratamento de doenças autoimunes
DK0666985T3 (da) Kompakteringsanalysemetode til vurdering af behandling af respiratoriske sygdomme
Slocombe et al. Evaluation of ivermectin against later fourth-stage Strongylus vulgaris in ponies at two and five weeks after treatment
Fluur et al. Gout in the temporomandibular joint: report on a case
KR910009255A (ko) 과트리글리세라이드혈증과, 콜레스테롤혈증, 저레벨의 hdl질환 및 아테롬성 동맥경화증 치료제로서 사용되는 2-(페녹시 프로파놀아미노)에톡시 페녹시아세트산 유도체
RU94016314A (ru) Способ пластики-задне-боковой стенки реконструированной гортани
Gewirtz The intravenous drug abuse patient
Kuznetsov et al. Case of Kawasaki's disease in the maritime territory
Bishara et al. Lichenoid reaction in bone marrow transplants suffering from chronic GVHD is associated with HLA-DQW1
Shahan et al. LAURA K. RICHMAN AND RICHARD J. MONTALI

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties